Long‑term surviving patient with EGFR mutation – deletion on exon 19 and acquired resistant mutation T790 – case report
06/2020
MUDr. Gabriela Krákorová, Ph.D.1; doc. MUDr. Jan Baxa, Ph.D.2; prof. MUDr. Miloš Pešek, CSc.
1 Klinika pneumologie a ftizeologie LF UK a FN Plzeň
2 Klinika zobrazovacích metod LF UK a FN Plzeň
SUMMARY
Metastatic lung cancer has a very poor prognosis, with a 5-year survival of about 5%. Pulmonary malignancies with a control mutation for which biologically targeted drugs are available have a better prognosis, as shown by a case report of a patient with a sensitive control EGFR mutation. Tumor biopsy and peripheral blood sampling, liquid biopsy, were performed repeatedly during treatment to detect the acquired T790 resistance mutation, among other things. The patient survives with metastatic lung adenocarcinoma for eight years, still with a good quality of life. The case report shows that due to a suitably selected treatment sequence according to the presumed or known genetic profile of the tumor, even metastatic lung cancer can change from such a serious disease to a chronic one.
Key words
metastatic lung cancer, EGFR, deletion, exon 19, erlotinib, control mutations, T790, osimertinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...